From: Anti-neuron antibody syndrome: clinical features, cytokines/chemokines and predictors
Outcomes | Relapses | ||||||
---|---|---|---|---|---|---|---|
Good outcomes | Poor outcomes | p | NO relapose | Relapses | p | ||
Types of onset | 0.0002 | Types of onset | 0.0163 | ||||
Acute | 43(58.90%) | 9(24.32%) | Acute | 31(40.26%) | 21(63.64%) | ||
Sub-acute | 9(12.33%) | 4(10.81%) | Sub-acute | 9(11.69%) | 4(12.12%) | ||
Chronic | 21(28.77%) | 24(64.86%) | Chronic | 37(48.05%) | 8(24.24%) | ||
Elevated CSF PRO | 0.0075 | Elevated CSF PRO | 0.0012 | ||||
No | 42(73.68%) | 11(42.31%) | NO | 29(51.79%) | 24(88.89%) | ||
Yes | 15(26.32%) | 15(57.69%) | YES | 27(48.21%) | 3(11.11%) | ||
Tumours | <0.0001 | MRI Flair/T2 abnormalities | 0.0345 | ||||
No | 57(81.43%) | 13(18.57%) | NO | 52(73.24%) | 14(50.00%) | ||
Yes | 16(40.00%) | 24(60.00%) | YES | 19(26.76%) | 14(50.00%) | ||
AE or PNS | 0.0004 | AE or PNS | 0.0113 | ||||
AE | 37(50.68%) | 6(16.22%) | AE | 24(55.81%) | 19(44.19%) | ||
PNS | 36(49.32%) | 31(83.78%) | PNS | 53(79.10%) | 14(20.90%) | ||
Serum CXCL10 | 38.02(7.84-525.63) | 48.77(7.58-516.68) | 0.0258 | Serum CXCL10 | 46.73(7.58-525.63) | 36.11(9.00-211.62) | 0.0279 |
Serum BAFF | 1094(440.36-5882.00) | 1266.5(531.88-4173.00) | 0.0409 | Serum TGFβ1 | 41401.57(13345.38-113337.9) | 64140.37(15755.87-122994.8) | 0.0032 |
CSF leukocytosis | 0.0606 | ||||||
No | 33(57.89%) | 9(34.62%) | |||||
Yes | 24(42.11%) | 17(65.38%) | |||||
CSF abnormality | 0.0889 | ||||||
No | 25(43.86%) | 6(23.08%) | |||||
Yes | 32(56.14%) | 20(76.92%) |